News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,235 Results
Type
Article (13763)
Company Profile (101)
Press Release (251371)
Section
Business (88039)
Career Advice (465)
Deals (15342)
Drug Delivery (67)
Drug Development (36600)
Employer Resources (49)
FDA (6289)
Job Trends (6197)
News (150204)
Policy (14027)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23214)
ALS (36)
Alzheimer's disease (390)
Antibody-drug conjugate (ADC) (37)
Approvals (6326)
Artificial intelligence (104)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (585)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (21)
Cell therapy (85)
Cervical cancer (4)
Clinical research (30880)
Collaboration (325)
Compensation (138)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (607)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1317)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32079)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37408)
Executive appointments (359)
FDA (6687)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (205)
Gene editing (37)
Generative AI (8)
Gene therapy (100)
GLP-1 (339)
Government (1286)
Grass and pollen (2)
Guidances (15)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (178)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (79)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (143)
MASH (31)
Medical device (1275)
Medtech (1277)
Mergers & acquisitions (9658)
Metabolic disorders (246)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (563)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (680)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (44)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28876)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8037)
Phase II (13062)
Phase III (11728)
Pipeline (416)
Podcasts (46)
Policy (59)
Postmarket research (1401)
Preclinical (3211)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2634)
Recruiting (17)
Regulatory (10090)
Reports (14)
Research institute (564)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (36)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (695)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
Tariffs (10)
The Weekly (29)
United States (6902)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (23)
Last 7 days (245)
Last 30 days (927)
Last 365 days (11998)
2025 (3095)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20091)
Australia (2606)
California (1643)
Canada (874)
China (230)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39368)
Florida (308)
Georgia (36)
Idaho (9)
Illinois (186)
India (15)
Indiana (129)
Iowa (1)
Japan (86)
Kansas (56)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (245)
Massachusetts (1424)
Michigan (28)
Minnesota (90)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (726)
New Mexico (7)
New York (482)
North Carolina (381)
North Dakota (2)
Northern California (680)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (416)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (695)
Tennessee (34)
Texas (219)
Utah (33)
Virginia (70)
Washington D.C. (29)
Washington State (112)
Wisconsin (14)
265,235 Results for "rafarma pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rafarma Pharmaceutical news update
Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.
November 30, 2023
·
5 min read
BioMidwest
Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University
Rafarma Pharmaceuticals - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023.
December 11, 2023
·
3 min read
Rafarma Pharmaceuticals strengthens its position in Central Asia
Representatives of Rafarma Pharmaceuticals, Inc. visited Uzbekistan and discussed the prospects for the company’s development in the territory of the innovative research and production pharmaceutical cluster “Tashkent Pharma Park”.
April 29, 2022
·
3 min read
Rafarma’s Global Pharmaceutical Strategy At A Glance
Rafarma Pharmaceuticals, Inc. OTC: is an international biotechnological and pharmaceutical company that combines research centers and modern pharmaceutical production that meets international GMP standards.
May 18, 2021
·
3 min read
Rafarma’s Slavich Noya Technology Division Expands Printing Production
Rafarma Pharmaceuticals, Inc. is expanding its production capabilities as it is in active negotiations for the acquisition of two machines from BOBST, one of the world’s leading suppliers of substrate processing, printing and converting equipment and services for the label, flexible packaging, folding carton and corrugated board industries.
February 7, 2022
·
2 min read
Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build
Rafarma Pharmaceuticals, Inc.OTC:(RAFA) The scientific and technical council of the Agency for the Development of the Pharmaceutical Industry of Uzbekistan recognized the Rafarma Pharmaceuticals’ project for the construction of the Tashkent plant as the largest innovative project of the industrial zone of the Tashkent Pharma Park pharmaceutical cluster.
July 30, 2021
·
2 min read
Rafarma To Expand Proton Therapy Centers
Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce that RAFA is in active meetings the City Scientific University of Istanbul to establish a nuclear medicine and proton therapy center at the university.
May 7, 2021
·
2 min read
Rafarma Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan
Rafarma Pharmaceuticals, Inc. OTC: is pleased to announce its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan which is essentially the Health Department of Uzbekistan.
January 29, 2021
·
2 min read
Rafarma Embarks on Aggressive Global Partnerships Plan
Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022.
March 4, 2021
·
2 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
1 of 26,524
Next